GlassScriptPhysician profile
Britani L Congleton
NPI 1093040438
$6,281.15
in general payments reported to CMS, 2019-2025
61 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,326 · 2022: $1,290 · 2023: $1,319 · 2024: $1,051 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,565 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.92 | 2021-2025 | |
| Lilly USA, LLC | $450.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $418.60 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $277.10 | 2021-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $244.21 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $229.88 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.89 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.02 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $196.16 | 2021-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $184.33 | 2021-2025 | Gardasil 9, Belsomra, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $175.26 | 2021-2025 | Trintellix, Eohilia |
| Lundbeck LLC | $174.70 | 2021-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $171.82 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.14 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $136.27 | 2023-2025 | Auvelity |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britani Congleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.